ERK5

Isoforms Recommended:	ERK5

By Targets:	Epigenetic Reader Domain (1) ERK (16) FGFR (1) MEK (2) PROTACs (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (1) Inflammation/Immunology (1) Metabolic Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156450

ERK5-IN-5	ERK	Cancer
ERK5-IN-5 (compound 4a) is an *ERK5* kinase inhibitor with anticancer activity. ERK5-IN-5 exhibits good anti-proliferative activity with the IC₅₀ value of 6.23 µg/mL for A549 cells .

HY-128341

ERK5-IN-2	ERK	Cardiovascular Disease Cancer
ERK5-IN-2 is an orally active, sub-micromolar, selective *ERK5* inhibitor with IC₅₀s of 0.82 μM, 3 μM for *ERK5* and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis .

HY-14403

ERK5-IN-1

ERK Cancer

ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC₅₀ of 26 nM.

ERK5-IN-1	ERK	Cancer
ERK5-IN-1 is a potent *ERK5* inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC₅₀ of 26 nM.

HY-150606

ERK5-IN-4	ERK	Cancer
ERK5-IN-4 (compound 34b) is a potent and selective inhibitor of extracellular signal-related kinase 5 (ERK5). ERK5-IN-4 inhibits *ERK5* (full-length) and truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with an IC₅₀ of 77 nM and 300 nM, respectively .

HY-156451

ERK5-IN-6	ERK	Cancer
ERK5-IN-6 (compound 5J) is an *ERK5* kinase inhibitor with anticancer activity. ERK5-IN-6 exhibits good anti-proliferative activity with the IC₅₀ value of 4.56 µg/mL for A549 cells .

HY-150605

ERK5-IN-3	ERK	Cancer
ERK5-IN-3 (compound 33j) is a potent and selective *ERK5* (extracellular signal-related kinase 5) inhibitor, with an IC₅₀ of 6 nM. ERK5-IN-3 shows antiproliferation activity against Hela cells, with an IC₅₀ of 31 nM .

HY-149412

MHJ-627	ERK	Cancer
MHJ-627 is a potent *ERK5* (MAPK7) inhibitor (IC₅₀: 0.91 μM). MHJ-627 promotes the mRNA expression of tumor suppressors and anti-metastatic genes, and promotes cancer cell death .

HY-108886

JWG-071 1 Publications Verification	ERK	Cancer
JWG-071 is the kinase-selective chemical probe for *ERK5. JWG-071 inhibits ERK5* and LRRK2 with IC₅₀ values of 88nM and 109 nM, respectively .

HY-15665

XMD17-109

5 Publications Verification

ERK Cancer

XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC₅₀ of 162 nM.
HY-101846

AX-15836

3 Publications Verification

ERK Inflammation/Immunology Cancer

AX-15836 is a potent and selective ERK5 inhibitor with an IC₅₀ of 8 nM.

XMD17-109 5 Publications Verification	ERK	Cancer
XMD17-109 is a novel, specific *ERK-5* inhibitor, with an IC₅₀ of 162 nM.

AX-15836 3 Publications Verification	ERK	Inflammation/Immunology Cancer
AX-15836 is a potent and selective *ERK5* inhibitor with an IC₅₀ of 8 nM.

HY-107622

(E/Z)-BIX02188	Others	Metabolic Disease
(E/Z)-BIX02188 is a MEK5/ERK5 pathway inhibitor. (E/Z)-BIX02188 inhibits the catalytic function of purified MEK5 enzyme.(E/Z)-BIX02188 can be used for the role of MEK5/ERK5 pathway in various biological systems .

HY-112082

BAY885

ERK Cancer

BAY885 is a highly potent and selective ERK5 inhibitor with an IC₅₀ of 35 nM. BAY885 shows weak inhibition on others kinases .

BAY885	ERK	Cancer
BAY885 is a highly potent and selective *ERK5* inhibitor with an IC₅₀ of 35 nM. BAY885 shows weak inhibition on others kinases .

HY-12056

BIX02189 5+ Cited Publications	MEK ERK	Cancer
BIX02189 is a potent and selective *MEK5* inhibitor with an IC₅₀ of 1.5 nM. BIX02189 also inhibits *ERK5* catalytic activity with an IC₅₀ of 59 nM.

HY-12055

BIX02188 3 Publications Verification	MEK ERK	Cancer
BIX02188 is a potent *MEK5*-selective inhibitor with an IC₅₀ of 4.3 nM. BIX02188 inhibits *ERK5* catalytic activity, with an IC₅₀ of 810 nM.

HY-149616

PPM-3	PROTACs ERK	Cancer
PPM-3 is a potent and selective PROTAC ERK5 degrader, with an IC₅₀ of 62.4 nM. PPM-3 did not influence tumor cell growth directly. PPM-3 influences tumor development by affecting the differentiation of macrophages .

HY-14443

XMD8-92 Maximum Cited Publications 10 Publications Verification	ERK Epigenetic Reader Domain	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity .

HY-138215

ADTL-EI1712	ERK	Cancer
ADTL-EI1712 is a potent, orally active, and selective dual-target inhibitor of *ERK1* and *ERK5, inhibition rates of ERK*1/5 at 1 μM are 93.54% and 89.35%, respectively. ADTL-EI1712 can induce regulated cell death, a form of cell death that relies on the activation of genetically encoded machinery, to overcome compensatory mechanism in specific cancer cells in vitro and in vivo .

HY-15813

FIIN-1 FGFR irreversible inhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to FGFR1/2/3/4 and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .

Cat. No.	Product Name

HY-L010

MAPK Compound Library	519 compounds
MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers. MCE designs a unique collection of 519 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

MAPK Compound Library

519 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 519 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Product Name	Application	Reactivity

HY-P80122

ERK5 Antibody	WB, ICC/IF, IP, FC	Human, Mouse
ERK5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 115 kDa, targeting to ERK5. It can be used for WB,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.